Background: Several cardiovascular risk factors have been suggested to be associated with
anthracycline-induced cardiotoxicity, but their quantitative effects have not reached a …

Background Empagliflozin (EMPA), a selective inhibitor of the sodium glucose co-transporter
2, reduced the risk of hospitalization for heart failure and cardiovascular death in type 2 …

Simple Summary The assessment of global longitudinal strain (GLS) has an established role
in cardio-oncology in the early diagnosis of the cardiotoxicity of anticancer treatments …

The most common cancer diagnosis in female population is breast cancer, which affects
every year about 2.0 million women worldwide. In recent years, significant progress has …

Improved risk stratification of patients during HER2-targeted therapy and effective prevention
and management strategies for cardiotoxicity are needed to enhance the value of …

Background Left ventricular dysfunction and cardiomyopathy are well documented adverse
effects associated with chemotherapy agents. Limited information exists regarding the …

Transthoracic echocardiography is the primary cardiac imaging modality for the detection of
Cancer Therapeutics‐Related Cardiac Dysfunction (CTRCD) through evaluation of serial …

Simple Summary Cancer therapy-related cardiac dysfunction (CTRCD) has been an urgent
medical issue in patients that receive breast cancer therapies including anthracycline-based …

Breast cancer is the most common form of cancer in women and its incidence has been
increasing over the years. Human epidermal growth factor receptor 2 (HER2 or ErbB2) …

Background Breast cancer (BC) radiotherapy (RT) can induce cardiotoxicity, with adverse
events often observed many years after BC RT. Subclinical left ventricular (LV) dysfunction …